{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unresectable+Locally+Advanced+or+Metastatic+Cancer&page=7",
    "query": {
      "condition": "Unresectable Locally Advanced or Metastatic Cancer",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 349,
    "total_pages": 35,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unresectable+Locally+Advanced+or+Metastatic+Cancer&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unresectable+Locally+Advanced+or+Metastatic+Cancer&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T09:39:48.422Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03761095",
      "title": "A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leiomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Unesbulin",
          "type": "DRUG"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PTC Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2019-03-13",
      "completion_date": "2024-02-05",
      "has_results": false,
      "last_update_posted_date": "2024-03-15",
      "last_synced_at": "2026-11-15T09:39:48.422Z",
      "location_count": 4,
      "location_summary": "Jacksonville, Florida • Baltimore, Maryland • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03761095"
    },
    {
      "nct_id": "NCT02625623",
      "title": "Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma",
        "Gastric Cancer Third Line"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Best Supportive Care (BSC)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 371,
      "start_date": "2015-12-28",
      "completion_date": "2019-11-13",
      "has_results": true,
      "last_update_posted_date": "2020-11-24",
      "last_synced_at": "2026-11-15T09:39:48.422Z",
      "location_count": 28,
      "location_summary": "Denver, Colorado • Pueblo, Colorado • Miami, Florida + 24 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Pueblo",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02625623"
    },
    {
      "nct_id": "NCT00471146",
      "title": "Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Pancreatic Ductal"
      ],
      "interventions": [
        {
          "name": "AG-013736",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 630,
      "start_date": "2007-07",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2012-07-16",
      "last_synced_at": "2026-11-15T09:39:48.422Z",
      "location_count": 77,
      "location_summary": "Antioch, California • Corona, California • Glendora, California + 57 more",
      "locations": [
        {
          "city": "Antioch",
          "state": "California"
        },
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "Glendora",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00471146"
    },
    {
      "nct_id": "NCT03002805",
      "title": "CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "CBT-1®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CBA Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2018-03-29",
      "completion_date": "2020-09",
      "has_results": false,
      "last_update_posted_date": "2019-08-19",
      "last_synced_at": "2026-11-15T09:39:48.422Z",
      "location_count": 6,
      "location_summary": "Santa Monica, California • Jacksonville, Florida • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03002805"
    },
    {
      "nct_id": "NCT05207722",
      "title": "CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic HER2 Positive Gastroesophageal Junction Cancer"
      ],
      "interventions": [
        {
          "name": "CYNK-101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Recombinant Human Interleukin-2",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Celularity Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1,
      "start_date": "2022-04-14",
      "completion_date": "2024-02-15",
      "has_results": false,
      "last_update_posted_date": "2024-12-12",
      "last_synced_at": "2026-11-15T09:39:48.422Z",
      "location_count": 3,
      "location_summary": "La Jolla, California • Washington D.C., District of Columbia • Hackensack, New Jersey",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05207722"
    },
    {
      "nct_id": "NCT04768881",
      "title": "Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Unresectable or Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Selinexor",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Karyopharm Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2021-05-12",
      "completion_date": "2023-09-22",
      "has_results": true,
      "last_update_posted_date": "2024-08-23",
      "last_synced_at": "2026-11-15T09:39:48.422Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Pasadena, California • Plantation, Florida + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "North Platte",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04768881"
    },
    {
      "nct_id": "NCT06669572",
      "title": "Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Squamous Cell",
        "Anorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2025-07-11",
      "completion_date": "2029-03-26",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-11-15T09:39:48.422Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06669572"
    },
    {
      "nct_id": "NCT06005974",
      "title": "A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "AXIN1 Gene Mutation",
        "APC Gene Mutation",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "REC-4881",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Recursion Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2024-01-15",
      "completion_date": "2025-02-24",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-11-15T09:39:48.422Z",
      "location_count": 13,
      "location_summary": "San Diego, California • Santa Barbara, California • Denver, Colorado + 10 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Norwich",
          "state": "Connecticut"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06005974"
    },
    {
      "nct_id": "NCT02426125",
      "title": "A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Ramucirumab",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 530,
      "start_date": "2015-07-13",
      "completion_date": "2022-07-26",
      "has_results": true,
      "last_update_posted_date": "2023-08-21",
      "last_synced_at": "2026-11-15T09:39:48.422Z",
      "location_count": 33,
      "location_summary": "Fayetteville, Arkansas • Fullerton, California • Los Angeles, California + 28 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02426125"
    },
    {
      "nct_id": "NCT03682068",
      "title": "Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Unresectable Locally Advanced Urothelial Cancer",
        "Metastatic Urothelial Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin + Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin + Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 1246,
      "start_date": "2018-09-27",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-11-15T09:39:48.422Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Bakersfield, California • Fullerton, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Salinas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03682068"
    }
  ]
}